Oscar, I disagree with your second paragraph regarding "dilutingh their resources". If Newjos post is accurate they are concentrating by proving their technology across 42 differant drugs. They probably won;t take any drugs to market on the own.
Their strategy is to license or co-develop all their products. The technology has such a broad range of applications it would be well beyond their ability to maximise its potential alone.
PoS.
poh negatives, page-4
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $205 | 72.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 90468113 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 61728026 | 18 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |